Paris - Delayed Quote EUR

Innate Pharma S.A. (IPH.PA)

1.9480

+0.0120

+(0.62%)

As of 9:41:02 AM GMT+2. Market Open.

Innate Pharma Announces Its Participation in Jefferies and Goldman Sachs Healthcare Conferences

MARSEILLE, France, May 27, 2025--Innate Pharma announces its participation in upcoming investor conferences

Business Wire 7 days ago

IPHA

IPHYF
Innate Pharma Highlights Durable Responses to Lacutamab in Sezary Syndrome and Mycosis Fungoides

MARSEILLE, France, May 23, 2025--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company") today announced the presentation of long-term follow-up data from the Phase 2 TELLOMAK clinical trial evaluating lacutamab, an anti-KIR3DL2 monoclonal antibody, in patients with Sézary syndrome (SS) and mycosis fungoides (MF), two rare and aggressive forms of cutaneous T-cell lymphoma (CTCL). The results will be presented at the American Society of Clinical Oncology

Business Wire 11 days ago

IPHA

IPHYF
Outcome of Innate Pharma’s 2025 Annual General Meeting

MARSEILLE, France, May 23, 2025--Outcome of Innate Pharma’s 2025 Annual General Meeting

Business Wire 11 days ago

IPHA

IPHYF
Innate Pharma Highlights Abstracts Selected for ASCO 2025 Annual Meeting

MARSEILLE, France, May 19, 2025--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company") announced today that four abstracts with Innate’s drugs in clinical development have been accepted for the American Society of Clinical Oncology (ASCO) 2025 Annual Meeting, taking place May 30-June 3, 2025 in Chicago, Illinois.

Business Wire 15 days ago

IPHA

IPHYF
Innate Pharma Highlights ANKET® Abstracts Selected for the EHA 2025 Congress

MARSEILLE, France, May 15, 2025--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company") today announced that an abstract regarding IPH6501, its ANKET® targeting CD20 B cells currently developed in relapsed and/or refractory Non-Hodgkin Lymphoma, has been selected for the European Hematology Association (EHA) Congress 2025, taking place June 12-15 in Milan, Italy.

Business Wire 19 days ago

IPHA

IPHYF
Innate Pharma Reports First Quarter 2025 Business Update and Financial Results

MARSEILLE, France, May 13, 2025--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company") today reported its consolidated financial results for the quarter ending March 31, 2025.

Business Wire 21 days ago

IPHA

IPHYF
Number of Shares and Voting Rights of Innate Pharma as of May 5, 2025

MARSEILLE, France, May 12, 2025--Regulatory News: Pursuant to the article L. 233-8 II of the French "Code de Commerce" and the article 223-16 of the French stock-market authorities (Autorité des Marchés Financiers, or "AMF") General Regulation, Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company") releases its total number of shares outstanding as well as its voting rights as at May 5, 2025:

Business Wire 22 days ago

IPHA

IPHYF
Innate Pharma announces conference call and webcast for Q1 2025 business update

MARSEILLE, France, May 06, 2025--Innate Pharma announces conference call and webcast for Q1 2025 business update

Business Wire 28 days ago

IPHA

IPHYF
Innate Pharma Files Its 2024 Universal Registration Document (Document d’enregistrement universel) and 2024 Annual Report on Form 20-F

MARSEILLE, France, April 30, 2025--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company") today announced the filing of its 2024 Universal Registration Document (Document d’enregistrement universel) for the year ending December 31, 2024 with the French market authority "Autorité des Marchés Financiers" ("AMF") on April 30, 2025. It can be downloaded (in French) on the Company’s website and on the AMF’s website.

Business Wire last month

IPHA

IPHYF
Innate Pharma Highlights Preclinical Anti-Tumor Efficacy Data of Its Antibody Drug Conjugate IPH4502 at the AACR 2025 Annual Meeting

MARSEILLE, France, April 29, 2025--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company") today shared new preclinical data for IPH4502, its novel and differentiated topoisomerase I inhibitor Antibody Drug Conjugate (ADC) targeting Nectin-4. The data were presented at the American Association for Cancer Research (AACR) Annual Meeting 2025.

Business Wire last month

IPHA

IPHYF
Innate Pharma And 2 Other European Penny Stocks To Watch

European markets have recently shown resilience, with the STOXX Europe 600 Index climbing 2.77% amid easing trade tensions between the U.S. and China, providing a positive backdrop for investors. In such a climate, penny stocks—though an older term—remain relevant as they often represent smaller or less-established companies that can offer substantial value when backed by solid financials. By identifying those with strong balance sheets and clear growth potential, investors may uncover...

Simply Wall St. last month

FSOYF

IPHA

IPHYF
Number of Shares and Voting Rights of Innate Pharma as of April 25, 2025

MARSEILLE, France, April 28, 2025--Number of shares and voting rights of Innate Pharma as of April 25, 2025

Business Wire last month

IPHA

IPHYF
French Drugmaker Sanofi Clocks 20% Q1 Profit Growth, Forecasts Strong Rebound In Annual Profit

Sanofi SA (NASDAQ:SNY) reported Thursday a first-quarter 2025 business operating income of 2.9 billion euros ($3.06 billion), up 20.1% year over year and 18.7% in constant currency. The company reported first-quarter sales of 9.89 billion euros ($10.42 billion), beating the consensus of $9.77 billion. This was driven by launches, Dupixent, and favorable Beyfortus phasing. Sales increased 10.8% year over year and 9.7% on constant currency. U.S. sales were 4.66 billion and increased by 15.4%. The

Benzinga last month

SNY

IPH.PA
+0.62%
Innate Pharma Announces €15M Investment by Sanofi

MARSEILLE, France, April 24, 2025--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company") today announces a €14,999,998.59 capital increase subscribed by Sanofi.

Business Wire last month

IPHA

IPHYF
Sanofi to Invest $17.2 Million in Innate Pharma as Part of Review of 2016 License Agreement

Innate Pharma SA (IPHA) and Sanofi (SNY) have agreed that the latter will invest up to 15 million eu

Premium
MT Newswires last month

IPH.PA
+0.62%

SNY
Innate Pharma Regains Its Rights on CD123 Targeting ANKET® and Announces Sanofi’s Intention to Make a Strategic Investment in the Company

MARSEILLE, France, April 23, 2025--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company") today announce review of their January 2016 Research Collaboration and License Agreement (the "2016 Agreement") with Sanofi:

Business Wire last month

IPHA

IPHYF
Innate Pharma to Hold Its Annual General Meeting of Shareholders on May 22, 2025

MARSEILLE, France, April 16, 2025--Innate Pharma to hold its Annual General Meeting of shareholders on May 22, 2025

Business Wire last month

IPHA

IPHYF
Innate Pharma Proposes to Its Shareholders to Transform Its Corporate Governance Structure Into a Board of Directors and to Change Its Composition

MARSEILLE, France, April 16, 2025--Innate Pharma proposes to its shareholders to transform its corporate governance structure into a board of directors and to change its composition

Business Wire last month

IPHA

IPHYF
Innate Pharma to Participate in the 2025 Stifel Virtual Targeted Oncology Forum

MARSEILLE, France, April 03, 2025--Innate Pharma to participate in the 2025 Stifel Virtual Targeted Oncology Forum

Business Wire last month

IPHA

IPHYF
European Penny Stocks To Watch In March 2025

European markets have recently faced challenges, with the pan-European STOXX Europe 600 Index ending about 1.4% lower due to new U.S. trade tariffs, despite earlier optimism from positive economic updates and geopolitical developments. In such a climate of uncertainty, investors often turn their attention to penny stocks—smaller or less-established companies that can offer unique value propositions. While the term "penny stocks" may seem outdated, these investments can still provide...

Simply Wall St. 2 months ago

IPHA

IPHYF

AGF-B.CO

Performance Overview

Return	IPH.PA	CAC 40 (^FCHI)
YTD	+0.83%	+4.60%
1-Year	-22.85%	-3.47%
3-Year	-32.69%	+19.04%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Innate Pharma S.A. (IPH.PA)

Innate Pharma Announces Its Participation in Jefferies and Goldman Sachs Healthcare Conferences

Innate Pharma Highlights Durable Responses to Lacutamab in Sezary Syndrome and Mycosis Fungoides

Outcome of Innate Pharma’s 2025 Annual General Meeting

Innate Pharma Highlights Abstracts Selected for ASCO 2025 Annual Meeting

Innate Pharma Highlights ANKET® Abstracts Selected for the EHA 2025 Congress

Innate Pharma Reports First Quarter 2025 Business Update and Financial Results

Number of Shares and Voting Rights of Innate Pharma as of May 5, 2025

Innate Pharma announces conference call and webcast for Q1 2025 business update

Innate Pharma Files Its 2024 Universal Registration Document (Document d’enregistrement universel) and 2024 Annual Report on Form 20-F

Innate Pharma Highlights Preclinical Anti-Tumor Efficacy Data of Its Antibody Drug Conjugate IPH4502 at the AACR 2025 Annual Meeting

Innate Pharma And 2 Other European Penny Stocks To Watch

Number of Shares and Voting Rights of Innate Pharma as of April 25, 2025

French Drugmaker Sanofi Clocks 20% Q1 Profit Growth, Forecasts Strong Rebound In Annual Profit

Innate Pharma Announces €15M Investment by Sanofi

Sanofi to Invest $17.2 Million in Innate Pharma as Part of Review of 2016 License Agreement

Innate Pharma Regains Its Rights on CD123 Targeting ANKET® and Announces Sanofi’s Intention to Make a Strategic Investment in the Company

Innate Pharma to Hold Its Annual General Meeting of Shareholders on May 22, 2025

Innate Pharma Proposes to Its Shareholders to Transform Its Corporate Governance Structure Into a Board of Directors and to Change Its Composition

Innate Pharma to Participate in the 2025 Stifel Virtual Targeted Oncology Forum

European Penny Stocks To Watch In March 2025

Performance Overview